Century Therapeutics (IPSC) Short-term Investments (2020 - 2026)
Century Therapeutics (IPSC) posted quarterly Short-term Investments of $83.8 million for Q1 2026, down 26.05% year-over-year from $113.3 million in Q1 2025, and up 51.56% quarter-over-quarter from $55.3 million in Q4 2025.
Century Therapeutics (IPSC) Short-term Investments (2020 - 2026) Analysis & Trends
Century Therapeutics (IPSC) has reported Short-term Investments for 7 consecutive years, with $83.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Short-term Investments fell 26.05% year-over-year to $83.8 million; the TTM figure through Mar 2026 stood at $83.8 million (down 26.05% YoY), while the FY2025 annual figure was $55.3 million, down 57.77% from the prior year.
- Short-term Investments climbed to $83.8 million in Q1 2026 per IPSC's latest filing, from $55.3 million in the prior quarter.
- Across five years, Short-term Investments topped out at $266.0 million in Q2 2022 and bottomed at $55.3 million in Q4 2025.
- Historically, Short-term Investments has averaged $145.8 million across 5 years, with a median of $130.9 million in 2024.
- Annual changes were most pronounced in 2022 — Short-term Investments jumped 112.28% — and 2023, when it slumped 65.43%.
- Century Therapeutics' Short-term Investments stood at $231.2 million in 2022, then slumped by 45.76% to $125.4 million in 2023, then advanced by 4.34% to $130.9 million in 2024, then plunged by 57.77% to $55.3 million in 2025, then soared by 51.56% to $83.8 million in 2026.
- Business Quant data shows IPSC's Short-term Investments at $83.8 million in Q1 2026, $55.3 million in Q4 2025, and $77.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Century Therapeutics | 346.65 Mn | 86.58 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 70.07 Mn |
| Mar 31, 2026 | 83.76 Mn |
| Dec 31, 2025 | 55.26 Mn |
| Sep 30, 2025 | 77.23 Mn |
| Jun 30, 2025 | 98.97 Mn |
| Mar 31, 2025 | 113.26 Mn |
| Dec 31, 2024 | 130.85 Mn |
| Sep 30, 2024 | 145.52 Mn |
| Jun 30, 2024 | 154.95 Mn |
| Mar 31, 2024 | 145.20 Mn |
| Dec 31, 2023 | 125.41 Mn |
| Sep 30, 2023 | 114.20 Mn |
| Jun 30, 2023 | 91.96 Mn |
| Mar 31, 2023 | 164.64 Mn |
| Dec 31, 2022 | 231.23 Mn |
| Sep 30, 2022 | 244.51 Mn |
| Jun 30, 2022 | 265.97 Mn |
| Mar 31, 2022 | 234.98 Mn |
| Dec 31, 2021 | 166.43 Mn |
| Sep 30, 2021 | 193.86 Mn |